Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H26ClNO6 |
Molecular Weight | 399.866 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C
InChI
InChIKey=JXTAALBWJQJLGN-KSSFIOAISA-N
InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
Arbaclofen (STX209, R-baclofen), a selective agonist of GABA-B receptors, has been investigated in clinical trials for the treatment of autism spectrum disorder ASD, phase II and for the treatment of patients with fragile X syndrome in phase III. As a result, the drug did not meet the primary outcome of improved social avoidance in FXS in either study. In spite of positive results in some children with ASD, further study will be needed to replicate and extend these initial findings. Arbaclofen has also been investigated in phase III clinical trials as a treatment for spasticity due to multiple sclerosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22993295 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28616094
5 mg BID to 15 mg TID
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2199
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C76088
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
DB08892
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
DTXSID40233754
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
300000034033
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
m2028
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
SS-38
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
ARBACLOFEN PLACARBIL
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107312
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
8861
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
11281011
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
847353-30-4
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
W89H91R7VX
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY | |||
|
C543531
Created by
admin on Sat Dec 16 17:24:17 GMT 2023 , Edited by admin on Sat Dec 16 17:24:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD